EF-G

Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 7, 2021
Health, Pharmaceutical, Chemistry, Protein biosynthesis, Physical sciences, Branches of biology, Diols, Fusidic acid, Desiccants, Protein synthesis inhibitor, EF-G, Sodium, Elongation factor

"SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.

Key Points: 
  • "SODIUM FUSIDATE ORAL - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome.
  • What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?